Moderna to Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10

Rhea-AI Summary

Moderna, Inc. (Nasdaq: MRNA) announced it will host a live conference call on the Phase 1 interim analysis of its seasonal influenza vaccine candidate, mRNA-1010, on December 10, 2021, at 8:00 a.m. ET. Investors can access the call by dialing 866-922-5184 (domestic) or 409-937-8950 (international), referencing conference ID 8748887. A webcast will also be available on the Moderna website. Since its inception, Moderna has transformed into a leader in mRNA therapeutics, with a diverse clinical portfolio and significant manufacturing capabilities.

Positive

• Scheduled live conference call to discuss Phase 1 interim analysis of mRNA-1010.
• Broad clinical portfolio in vaccines and therapeutics with strong market presence.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will host a live conference call and webcast on the Phase 1 interim analysis of its seasonal influenza vaccine candidate, mRNA-1010 tomorrow, Friday, December 10, 2021 at 8:00 a.m. ET.

To access the call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 8748887. A webcast of the call will also be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. The archived webcast will be available on Moderna’s website approximately two hours after the conference call.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211209006075/en/

Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com

 

Source: Moderna, Inc.

FAQ

What is the purpose of Moderna's conference call on December 10, 2021?

The conference call will discuss the Phase 1 interim analysis of Moderna's seasonal influenza vaccine candidate, mRNA-1010.

Where can I access the webcast of Moderna's conference call?

The webcast can be accessed under 'Events and Presentations' in the Investors section of Moderna's website.

What is mRNA-1010?

mRNA-1010 is Moderna's seasonal influenza vaccine candidate currently in Phase 1 testing.

What impact does the Phase 1 analysis of mRNA-1010 have on Moderna's stock?

The results of the Phase 1 analysis could influence investor sentiment and stock performance for MRNA.